

Supplemental Table 1: Patients with definite or unclear metastatic deposits according to NaF PET/CT.

Patient	Bone metastases according to NaF PET/CT*	PSA value at six weeks and six months after radical prostatectomy	Additional imaging during 24 months of follow up	Clinical follow up and PSA levels after radical prostatectomy – 24 months of follow up
1	Bone metastases present	<0.1 ng/mL	ceCT at 24 months without bone metastases	PSA levels < 0.1 ng/mL at 12 and 24 months after radical prostatectomy. No skeletal related symptoms
2	Equivocal	<0.1 ng/mL	No additional imaging during follow up	PSA levels < 0.1 ng/mL at 12 and 24 months after radical prostatectomy. No skeletal related symptoms
3	Equivocal	<0.1 ng/mL	No additional imaging during follow up	PSA levels < 0.1 ng/mL at 12 and 24 months after radical prostatectomy. No skeletal related symptoms
4	Equivocal	<0.1 ng/mL	No additional imaging during follow up	PSA levels < 0.1 ng/mL at 12 and 24 months after radical prostatectomy. No skeletal related symptoms
5	Equivocal	<0.1 ng/mL	No additional imaging during follow up	PSA levels < 0.1 ng/mL at 12 and 24 months after radical prostatectomy. No skeletal related symptoms
6	Equivocal	<0.1 ng/mL	ceCT at 24 months without bone metastases	PSA levels < 0.1 ng/mL at 12 and 24 months after radical prostatectomy. No skeletal related symptoms
7	Equivocal	<0.1 ng/mL	ceCT at 15 months without bone metastases	PSA levels < 0.1 ng/mL at 12 and 24 months after radical prostatectomy. No skeletal related symptoms
8	Equivocal	<0.1 ng/mL	No additional imaging during follow up	PSA levels < 0.1 ng/mL at 12 and 24 months after radical prostatectomy. No skeletal related symptoms

* Consensus diagnosis of blinded observers (three point scale).
ceCT: contrast enhanced CT